3,027 results on '"Cheng, Allen"'
Search Results
202. Tumor Cell Cycle Arrest Induced by Shear Stress: Roles of Integrins and Smad
- Author
-
Chang, Shun-Fu, Chang, Cheng Allen, Lee, Ding-Yu, Lee, Pei-Ling, Yeh, Yu-Ming, Yeh, Chiuan-Ren, Cheng, Cheng-Kung, Chien, Shu, and Chiu, Jeng-Jiann
- Published
- 2008
- Full Text
- View/download PDF
203. Correlation evaluation of antioxidant properties on the monosaccharide components and glycosyl linkages of polysaccharide with different measuring methods
- Author
-
Lo, Tiffany Chien-Ting, Chang, Cheng Allen, Chiu, Kong-Hwa, Tsay, Pei-Kwei, and Jen, Jen-Fon
- Published
- 2011
- Full Text
- View/download PDF
204. Aortic Root Dynamics and Surgery: From Craft to Science
- Author
-
Cheng, Allen, Dagum, Paul, and Miller, D. Craig
- Published
- 2007
- Full Text
- View/download PDF
205. Incidence of Catheter‐Related Bloodstream Infection Among Patients With a Needleless, Mechanical Valve–Based Intravenous Connector in an Australian Hematology‐Oncology Unit
- Author
-
Field, Kathryn, McFarlane, Caroline, Cheng, Allen C., Hughes, Andrew J., Jacobs, Elly, Styles, Kaylene, Low, Jillian, Stow, Peter, Campbell, Philip, and Athan, Eugene
- Published
- 2007
- Full Text
- View/download PDF
206. Risk perception, illusory superiority and personal responsibility during COVID‐19: An experimental study of attitudes to staying home
- Author
-
van Baal, Simon T., primary, Walasek, Lukasz, additional, Karanfilovska, Daniela, additional, Cheng, Allen C., additional, and Hohwy, Jakob, additional
- Published
- 2022
- Full Text
- View/download PDF
207. Surveillance for severe influenza and COVID-19 in patients admitted to sentinel Australian hospitals in 2020: the Influenza Complications Alert Network (FluCAN)
- Author
-
Begum, Husna, primary, Dwyer, Dominic E, additional, Holmes, Mark, additional, Irving, Louis B, additional, Simpson, Graham, additional, Senanayake, Sanjaya, additional, Korman, Tony, additional, Friedman, N Deborah, additional, Cooley, Louise, additional, Wark, Peter, additional, Bowler, Simon, additional, Kok, Jen, additional, Upham, John W, additional, Fatovich, Daniel M, additional, Waterer, Grant W, additional, Macartney, Kristine, additional, Blyth, Christopher C, additional, Crawford, Nigel, additional, Buttery, Jim, additional, Marshall, Helen S, additional, Clark, Julia E, additional, Francis, Joshua R, additional, Kotsimbos, Tom, additional, Kelly, Paul M, additional, and Cheng, Allen C, additional
- Published
- 2022
- Full Text
- View/download PDF
208. A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2
- Author
-
Fulford, Thomas S., primary, Van, Huy, additional, Gherardin, Nicholas A., additional, Zheng, Shuning, additional, Ciula, Marcin, additional, Drummer, Heidi E., additional, Redmond, Samuel, additional, Tan, Hyon-Xhi, additional, Boo, Irene, additional, Center, Rob J., additional, Li, Fan, additional, Grimley, Samantha L., additional, Wines, Bruce D., additional, Nguyen, Thi H.O., additional, Mordant, Francesca L., additional, Ellenberg, Paula, additional, Rowntree, Louise C., additional, Kedzierski, Lukasz, additional, Cheng, Allen C., additional, Doolan, Denise L., additional, Matthews, Gail, additional, Bond, Katherine, additional, Hogarth, P. Mark, additional, McQuilten, Zoe, additional, Subbarao, Kanta, additional, Kedzierska, Katherine, additional, Juno, Jennifer A., additional, Wheatley, Adam K., additional, Kent, Stephen J., additional, Williamson, Deborah A., additional, Purcell, Damian F.J., additional, Anderson, David A., additional, and Godfrey, Dale I., additional
- Published
- 2021
- Full Text
- View/download PDF
209. Design of a Tunnel Cooling System
- Author
-
Cheng, Allen, Dawson, Robert, Zhao, Richard, and Hale, Phyllis, editor
- Published
- 1994
- Full Text
- View/download PDF
210. Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial
- Author
-
Writing Committee for the REMAP-CAP Investigators, Estcourt, Lise J, Turgeon, Alexis F, McQuilten, Zoe K, McVerry, Bryan J, Al-Beidh, Farah, Annane, Djillali, Arabi, Yaseen M, Arnold, Donald M, Beane, Abigail, Bégin, Philippe, van Bentum-Puijk, Wilma, Berry, Lindsay R, Bhimani, Zahra, Birchall, Janet E, Bonten, Marc JM, Bradbury, Charlotte A, Brunkhorst, Frank M, Buxton, Meredith, Callum, Jeannie L, Chassé, Michaël, Cheng, Allen C, Cove, Matthew E, Daly, James, Derde, Lennie, Detry, Michelle A, De Jong, Menno, Evans, Amy, Fergusson, Dean A, Fish, Matthew, Fitzgerald, Mark, Foley, Claire, Goossens, Herman, Gordon, Anthony C, Gosbell, Iain B, Green, Cameron, Haniffa, Rashan, Harvala, Heli, Higgins, Alisa M, Hills, Thomas E, Hoad, Veronica C, Horvat, Christopher, Huang, David T, Hudson, Cara L, Ichihara, Nao, Laing, Emma, Lamikanra, Abigail A, Lamontagne, François, Lawler, Patrick R, Linstrum, Kelsey, Litton, Edward, Lorenzi, Elizabeth, MacLennan, Sheila, Marshall, John, McAuley, Daniel F, McDyer, John F, McGlothlin, Anna, McGuinness, Shay, Miflin, Gail, Montgomery, Stephanie, Mouncey, Paul R, Murthy, Srinivas, Nichol, Alistair, Parke, Rachael, Parker, Jane C, Priddee, Nicole, Purcell, Damian FJ, Reyes, Luis F, Richardson, Peter, Robitaille, Nancy, Rowan, Kathryn M, Rynne, Jennifer, Saito, Hiroki, Santos, Marlene, Saunders, Christina T, Serpa Neto, Ary, Seymour, Christopher W, Silversides, Jon A, Tinmouth, Alan A, Triulzi, Darrell J, Turner, Anne M, van de Veerdonk, Frank, Walsh, Timothy S, Wood, Erica M, Berry, Scott, Lewis, Roger J, Menon, David K, McArthur, Colin, Zarychanski, Ryan, Angus, Derek C, Webb, Steve A, Roberts, David J, Shankar-Hari, Manu, Menon, David [0000-0002-3228-9692], Apollo - University of Cambridge Repository, Investigators, Writing Committee for the REMAP-CAP, Writing Comm REMAP-CAP Investigators, Hôpital Raymond Poincaré [AP-HP], Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), National Institutes of Health, NIH, National Institute of Child Health and Human Development, NICHD, Pittsburgh Foundation, Breast Cancer Research Foundation, BCRF, Bristol-Myers Squibb, BMS, GlaxoSmithKline, GSK, Medtronic, Baxter International, Manitoba Medical Service Foundation, MMSF, CancerCare Manitoba Foundation, CCMF, Wellcome Trust, WT, University of Manitoba, UM, Health Research Board, HRB: PHRC-20-0147, National Blood Authority, NBA, Llywodraeth Cymru, Translational Breast Cancer Research Consortium, TBCRC, Canadian Institutes of Health Research, IRSC: 158584, CTN 2014-012, Medical Research Council, MRC, National Institute for Health Research, NIHR, Department of Health and Social Care, DH, European Commission, EC: APP194811, National Heart and Lung Institute, NHLI, National Health and Medical Research Council, NHMRC: 2015-06-18, 2016-16-011, APP1101719, APP2002132, Health Research Council of New Zealand, HRC: 16/631, 447335, Monash University, MU, Ministère des Affaires Sociales et de la Santé: 215522, Seventh Framework Programme, FP7, Université Pierre et Marie Curie, UPMC, Innovate UK, Horizon 2020, Pharmaceuticals Bayer, Minderoo Foundation, Dr Fitzgerald reported receiving grants from the PREPARE Network and the European Commission. Dr Gordon reported receiving grants from the National Institute for Health Research and receiving personal fees from 30 Respiratory, GlaxoSmithKline, and Bristol Myers Squibb. Dr Gosbell reported receiving grants from the Australian Red Cross Lifeblood, which is funded by the Australian government. Dr Haniffa reported receiving grants from the Wellcome Trust Innovations Project, the Minderoo Foundation, and the UK Research and Innovation African Critical Care Registry Network. Dr Higgins reported receiving grants from the National Health and Medical Research Council, the Minderoo Foundation, and the National Blood Authority. Dr Hills reported receiving grants from the Health Research Council of New Zealand. Dr Hoad reported receiving grants from the Australian Red Cross Lifeblood, which is funded by the Australian government. Dr Horvat reported receiving grants from the National Institute of Child Health and Human Development. Dr Huang reported receiving grants from the Breast Cancer Research Foundation. Dr Lamontagne reported receiving grants from the Canadian Institutes of Health Research. Dr Lawler reported receiving consulting fees from Novartis, Coronna LLC, and Brigham and Women’s Hospital, receiving royalties from McGraw-Hill Publishing, and receiving grants from the Canadian Institutes of Health Research, the LifeArc Foundation, the National Institutes of Health, the Peter Munk Cardiac Centre, the Ted Rogers Centre for Heart Research, the Thistledown Foundation, and the province of Ontario. Dr Lorenzi reported receiving personal fees from Berry Consultants. Dr Marshall reported receiving personal fees from AM-Pharma (data and safety monitoring board chair) and Critical Care Medicine (associate editor). Dr McAuley reported receiving personal fees from Bayer, GlaxoSmithKline, Boehringer Ingelheim, Novartis, Eli Lilly, Vir Biotechnology, Faron Pharmaceuticals, and Sobi, receiving grants from the National Institute for Health Research, Wellcome Trust, Innovate UK, the Medical Research Council, and the Northern Ireland Health and Social Care Research and Development Division, and holding a patent for an anti-inflammatory treatment that was issued to Queen’s University Belfast. Dr McGlothlin reported receiving grants from the PREPARE Network, the European Commission, and the Global Coalition for Adapative Research. Mr Mouncey reported receiving grants from the European Union, the PREPARE Network, the National Institute for Health Research, and European Union Horizon 2020. Dr Nichol reported receiving grants from the Health Research Board of Ireland and Baxter and receiving personal fees from AM-Pharma. Dr Parke reported receiving grants from Fisher and Paykel Healthcare Ltd. Ms Parker reported receiving grants from Monash University. Mr Richardson reported receiving funding from the Welsh government. Dr Rowan reported receiving grants from the European Commission and the National Institute for Health Research. Dr Saunders reported receiving grants from the PREPARE Network, the European Commission, and the Global Coalition for Adapative Research. Dr Serpa Neto reported receiving personal fees from Drager and Endpoint Health. Dr Tinmouth reported receiving grants and personal fees from the Canadian Blood Services. Ms Turner reported receiving grants from the Health Research Council of New Zealand. Dr van de Veerdonk reported receiving personal fees from Gilead, Sobi, and GlaxoSmithKline. Dr Wood reported receiving grants from the Australian Medical Research Future Fund. Dr S. Berry reported being an employee of Berry Consultants with an ownership role. Dr Lewis reported being an employee of Berry Consultants. Dr Menon reported receiving grants from the National Institute for Health Research. Dr McArthur reported receiving grants from the Health Research Council of New Zealand. Dr Zarychanski reported receiving grants from the Canadian Institutes of Health Research, the University of Manitoba, LifeArc, the Thistledown Foundation, Research Manitoba, the CancerCare Manitoba Foundation, the Victoria General Hospital Foundation, the Peter Munk Cardiac Centre, and the Manitoba Medical Services Foundation. Dr Webb reported receiving grants from the National Health and Medical Research Council and the Minderoo Foundation. Dr Shankar-Hari reported receiving grants from the National Institute for Clinical Research. No other disclosures were reported., nonprofit sponsors: Monash University, Melbourne, Australia (Australasian sponsor), Utrecht Medical Center, Utrecht, the Netherlands (European sponsor), St Michael’s Hospital, Toronto, Ontario, Canada (Canadian sponsor), and the Global Coalition for Adaptive Research, San Francisco, California (US sponsor). This study was additionally funded by grant 602525 FP7-health-2013-innovation-1 from the European Union Platform for European Preparedness Against Reemerging Epidemics, grants APP1101719 and APP1116530 from the Australian National Health and Medical Research Council, grant APP2002132 from the Australian Medical Research Future Fund, grant 16/631 from the New Zealand Health Research Council, grant 447335 from the Canadian Institutes of Health Research COVID-19 Rapid Research, grant 158584 from the Canadian Institutes of Health Research Strategy for Patient-Oriented Research Innovative Clinical Trials Program, grant CTN 2014-012 from the Health Research Board of Ireland, grant PHRC-20-0147 from the French Ministry of Health, and grant 215522 from the Wellcome Trust Innovations Project and funding from the National Institute for Health Research, the Department of Health and Social Care, the EU Programme Emergency Support Instrument, the NHS Blood and Transplant Research and Development Programme, the National Institute for Health Research, the National Institute for Health Research Imperial Biomedical Research Centre, the UPMC Learning While Doing Program, the Translational Breast Cancer Research Consortium, the Pittsburgh Foundation, and the Minderoo Foundation. The Australian government funds the Australian Red Cross Lifeblood for the provision of blood products and services. The collection of plasma in the United Kingdom was funded by European Union SoHo grants from the Department of Health and Social Care. Dr Turgeon is the Canada Research Chair in Critical Care Neurology and Trauma. Dr McQuilten is supported by emerging leader fellowship APP194811 from the National Health and Medical Research Council. Dr Gordon is funded by research professorship 2015-06-18 from the National Institute for Health Research. Dr Shankar-Hari is funded by clinician scientist fellowship 2016-16-011 from the National Institute for Health Research., In Canada, the trial has been funded by the Canadian Institute of Health Research, Strategy for Patient-Oriented Research (CIHR-SPOR) Innovative Clinical Trials Program Grant (no. 158584) for CAD $1,497,200, for the recruitment of 300 patients., The Platform for European Preparedness Against (Re-)emerging Epidemics (PREPARE) consortium is funded by the European Union (FP7-HEALTH-2013-INNOVATION-1, grant number 602525). Within the PREPARE consortium, the trial has funding for the recruitment of approximately 4000 patients., REMAP-CAP was supported in the Netherlands by the Research Collaboration Critical Care the Netherlands (RCC-Net)., Funding sources for the REMAP-CAP trial are specified in the core protocol documents. This domain has received domain-specific funding from the Australian Medical Research Future Fund (MRFF)., reported receiving grants from the National Institute for Health Research and European Union Horizon 2020. Dr Turgeon reported receiving grants from the Canadian Institutes of Health Research. Dr McQuilten reported receiving grants from the Australian Medical Research Future Fund. Dr McVerry reported receiving grants from the Pittsburgh Foundation, the Translational Breast Cancer Research Consortium, UPMC Learning While Doing Program, National Heart, Lung, and Blood Institute, and Bayer Pharmaceuticals and receiving personal fees from Boehringer Ingelheim. Dr Annane reported receiving grants from the French Ministry of Health and Solidarity. Dr Arnold reported receiving grants from the Canadian Institutes of Health Research. Ms Beane reported receiving grants and salary support from Wellcome Trust. Ms Bentum-Puijk reported receiving grants from the European Commission and the European Union. Dr L. Berry reported receiving grants from Berry Consultants. Dr Bradbury reported receiving personal fees from Lilly, Bristol Myers Squibb, Pfizer, Bayer, Amgen, Novartis, Janssen, Portola Advisors, and Ablynx. Dr Buxton reported receiving personal fees from the Breast Cancer Research Foundation, Amgen, and Eisai. Dr Callum reported receiving grants from the Canadian Blood Services and Octapharma. Dr Cove reported receiving grants from National University Health System, receiving consulting fees from Medtronic and Baxter, and holding a US patent for removal of carbon dioxide via dialysis. Dr Daly reported receiving grants from the Australian Red Cross Lifeblood, which is funded by the Australian government. Dr Derde reported receiving grants from University Medical Center Utrecht, being a member of the COVID-19 guideline committee of the Surviving Sepsis Campaign/ European Society of Intensive Care Medicine and European Society of Intensive Care Medicine COVID-19 taskforce, and serving as chair of the Dutch intensivists taskforce acute infectious threats. Dr Detry reported receiving grants from the European Union Platform for European Preparedness Against Reemerging Epidemics (PREPARE) consortium, the Australian National Health and Medical Research Council, the Health Research Council of New Zealand, and the UPMC Learning While Doing Program. Dr De Jong reported receiving personal fees from Roche Scientific, Shionogi Scientific, and Janssen., The current regions are: x Europe, with funding from a European Union FP7 grant (FP7-HEALTH-2013-INNOVATION-1, grant number 602525), to support the enrollment of 4000 participants. This funding terminates in 2021. x Australia and New Zealand. In Australia the project has received funding from a NHMRC Project Grant (APP1101719), to support the enrollment of 2000 participants. This funding terminates in December 2021, although some extension may be feasible. In New Zealand the project has received funding from a HRC Programme Grant (16/631), to support the enrollment of 800 participants. This funding terminates in November 2021. x Canada. In Canada the project has received funding for a CIHR grant (158584), to support the enrollment of 300 participants. This funding terminates in 2022. x United States. In the US, funding has been received from UPMC health system for recruitment internally at all UPMC hospitals (>40) and to support a US regional coordinating center. Philanthropic support is being provided through GCAR. Additional funds are being pursued., The REMAP-CAP platform is supported by the Australian and New Zealand Intensive Care Society Clinical Trials Group, the Canadian Critical Care Trials Group, the Irish Critical Care, European Project: 602525,EC:FP7:HEALTH,FP7-HEALTH-2013-INNOVATION-1,PREPARE(2014), NIHR, National Institute for Health Research, Medical Microbiology and Infection Prevention, AII - Infectious diseases, and Intensive Care Medicine
- Subjects
Male ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4] ,030204 cardiovascular system & hematology ,Logistic regression ,law.invention ,0302 clinical medicine ,Randomized controlled trial ,law ,Critical Illness/therapy ,Vasoconstrictor Agents ,030212 general & internal medicine ,Hospital Mortality ,Treatment Failure ,11 Medical and Health Sciences ,Original Investigation ,Mortality rate ,General Medicine ,Middle Aged ,Intensive care unit ,Writing Committee for the REMAP-CAP Investigators ,3. Good health ,Female ,Life Sciences & Biomedicine ,COVID-19/therapy ,Adult ,medicine.medical_specialty ,Randomization ,Respiration, Artificial/statistics & numerical data ,Critical Illness ,ABO Blood-Group System ,03 medical and health sciences ,Medicine, General & Internal ,Internal medicine ,General & Internal Medicine ,medicine ,Humans ,Adverse effect ,COVID-19 Serotherapy ,Aged ,Mechanical ventilation ,Science & Technology ,business.industry ,Immunization, Passive ,Vasoconstrictor Agents/therapeutic use ,COVID-19 ,Odds ratio ,Length of Stay ,Respiration, Artificial ,Logistic Models ,Human medicine ,business - Abstract
Importance The evidence for benefit of convalescent plasma for critically ill patients with COVID-19 is inconclusive.Objective To determine whether convalescent plasma would improve outcomes for critically ill adults with COVID-19.Design, Setting, and Participants The ongoing Randomized, Embedded, Multifactorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) enrolled and randomized 4763 adults with suspected or confirmed COVID-19 between March 9, 2020, and January 18, 2021, within at least 1 domain; 2011 critically ill adults were randomized to open-label interventions in the immunoglobulin domain at 129 sites in 4 countries. Follow-up ended on April 19, 2021.Interventions The immunoglobulin domain randomized participants to receive 2 units of high-titer, ABO-compatible convalescent plasma (total volume of 550 mL ± 150 mL) within 48 hours of randomization (n = 1084) or no convalescent plasma (n = 916).Main Outcomes and Measures The primary ordinal end point was organ support–free days (days alive and free of intensive care unit–based organ support) up to day 21 (range, −1 to 21 days; patients who died were assigned –1 day). The primary analysis was an adjusted bayesian cumulative logistic model. Superiority was defined as the posterior probability of an odds ratio (OR) greater than 1 (threshold for trial conclusion of superiority >99%). Futility was defined as the posterior probability of an OR less than 1.2 (threshold for trial conclusion of futility >95%). An OR greater than 1 represented improved survival, more organ support–free days, or both. The prespecified secondary outcomes included in-hospital survival; 28-day survival; 90-day survival; respiratory support–free days; cardiovascular support–free days; progression to invasive mechanical ventilation, extracorporeal mechanical oxygenation, or death; intensive care unit length of stay; hospital length of stay; World Health Organization ordinal scale score at day 14; venous thromboembolic events at 90 days; and serious adverse events.Results Among the 2011 participants who were randomized (median age, 61 [IQR, 52 to 70] years and 645/1998 [32.3%] women), 1990 (99%) completed the trial. The convalescent plasma intervention was stopped after the prespecified criterion for futility was met. The median number of organ support–free days was 0 (IQR, –1 to 16) in the convalescent plasma group and 3 (IQR, –1 to 16) in the no convalescent plasma group. The in-hospital mortality rate was 37.3% (401/1075) for the convalescent plasma group and 38.4% (347/904) for the no convalescent plasma group and the median number of days alive and free of organ support was 14 (IQR, 3 to 18) and 14 (IQR, 7 to 18), respectively. The median-adjusted OR was 0.97 (95% credible interval, 0.83 to 1.15) and the posterior probability of futility (OR Conclusions and Relevance Among critically ill adults with confirmed COVID-19, treatment with 2 units of high-titer, ABO-compatible convalescent plasma had a low likelihood of providing improvement in the number of organ support–free days.Trial Registration ClinicalTrials.gov Identifier: NCT02735707
- Published
- 2021
- Full Text
- View/download PDF
211. Upregulation of Bone Morphogenetic Protein-2 Synthesis and Consequent Collagen II Expression in Leptin-stimulated Human Chondrocytes.
- Author
-
Shun-Fu Chang, Rong-Ze Hsieh, Kuo-Chin Huang, Cheng Allen Chang, Fang-Yao Chiu, Hsing-Chun Kuo, Cheng-Nan Chen, and Yu-Ping Su
- Subjects
Medicine ,Science - Abstract
Bone morphogenetic proteins (BMPs) play positive roles in cartilage development, but they can barely be detected in healthy articular cartilage. However, recent evidence has indicated that BMPs could be detected in osteoarthritic and damaged cartilage and their precise roles have not been well defined. Extremely high amounts of leptin have been reported in obese individuals, which can be associated with osteoarthritis (OA) development. The aim of this study was to investigate whether BMPs could be induced in human primary chondrocytes during leptin-stimulated OA development and the underlying mechanism. We found that expression of BMP-2 mRNA, but not BMP-4, BMP-6, or BMP-7 mRNA, could be increased in human primary chondrocytes under leptin stimulation. Moreover, this BMP-2 induction was mediated through transcription factor-signal transducer and activator of transcription (STAT) 3 activation via JAK2-ERK1/2-induced Ser727-phosphorylation. Of note, histone deacetylases (HDACs) 3 and 4 were both involved in modulating leptin-induced BMP-2 mRNA expression through different pathways: HDAC3, but not HDAC4, associated with STAT3 to form a complex. Our results further demonstrated that the role of BMP-2 induction under leptin stimulation is to increase collagen II expression. The findings in this study provide new insights into the regulatory mechanism of BMP-2 induction in leptin-stimulated chondrocytes and suggest that BMP-2 may play a reparative role in regulating leptin-induced OA development.
- Published
- 2015
- Full Text
- View/download PDF
212. Contributors
- Author
-
Abubaker, A. Omar, Acero, Julio, Agarwal, Ravi, Aghaloo, Tara, Akbari, Maryam, Allen, Kyle P., Allon, Dror M., Almeida, Fernando, Alpert, Brian, Altay, Mehmet Ali, Amarista, Felix Jose, Amer, Hatem, Appugounder, Suganya, Aravindaksha, Shyam Prasad, Aronovich, Sharon, Assael, Leon, Awadallah, Michael, Aziz, Shahid R., Bagheri, Shahrokh C., Bailey, Jonathan, Baker, Andrew M., Bakri, Karim, Barnes, Suzanne, Bast, Brian, Batal, Hussam, Baur, Dale A., Bedrossian, Edmond, Bedrossian, Edmond Armand, Bell, R. Bryan, Bitonti, David A., Bohluli, Behnam, Bonin, Genevieve C., Bouloux, Gary F., Bradley, Meaghan, Breik, Omar, Brockhoff, Hans C., II, Buchbinder, Daniel, Bui, Tuan G., Byrne, Patrick, Caccamese, John Francis, Jr, Caloss, Ron, Caplin, Courtney, Carlson, Eric R., Casap, Nardy, Hill, Carrie E. Cera, Chakrabarti, Swagnik, Chandran, Ravi, Chaney, Blake, Cheng, Allen C., Chigurupati, Radhika, Cho, Nam, Chou, Joli, Christensen, Louis J., Cillo, Joseph E., Jr, Claiborne, Scott T., Collette, David, Contasti-Bocco, Gisela, Costello, Bernard J., Cotofana, Sebastian, Couey, Marcus A., Cunningham, Larry, Jr, Curtis, William J., L. Cuzalina, Angelo, Dang, Rushil R., Daniel, Renie, Dattilo, David J., Dean, Jeffrey S., Desai, Shaun C., Dillon, Jasjit K., Doucet, Jean-Charles, Drew, Stephanie Joy, Dyalram, Donita, Edwards, Sean P., Emam, Hany, Emmerling, Max R., Engelstad, Mark, Erickson, Helaman, Evasovich, Maria, Fagin, Adam P., Fanelli, Christopher A., Fantuzzo, Joseph J., Fattahi, Tirbod, Fernandes, Rui P., Finn, Richard Allen, Franco, Peter B., Gailey, David, Gangwani, Pooja, Ghali, Ghali E., Gibreel, Waleed, Girod, Sabine C., Golden, Brent, Gonzalez, Jorge, Gonzalez, Marianela, Granquist, Eric J., Grant, Jaime, Gray, Mingyang Liu, Guerrero, Cesar A., Hadaya, Danny, Hamlar, David, Hammer, Daniel A., Hanba, Curtis, Heggie, Andrew Alistair, Henriquez, Mariana, Henry, Andrew, Herford, Alan S., Herman, Brandyn, Hinkl, David, Holmes, Anthony David, Holton, James B., Hossaini-Zadeh, Mehran, Hossameldin, Reem H., Hsieh, Tsung-yen, Huang, Allen, Hughes, Pamela J., Hutchinson, Tanisha, Idle, Matthew R., Sunder Indrakanti, Shyam, Jaskolka, Michael, Jelmini, Jonathan James, Jensen, Ole T., Jethwa, Ashok R., Jones, Baxter, Kademani, Deepak, Kang, David R., Kao, Herman, Karlis, Vasiliki, Kim, Beomjune, Kim, D. David, Kim, Roderick Y., Kloostra, Paul, Kolokythas, Antonia, Koppel, David A., Krishnan, Deepak G., Kuriakose, Moni A., Lai, Li Han, Laster, Zvi, Laviv, Amir, Lee, Andrew W.C., Lewallen, James B., Yung-Chuan Liu, Stanley, Loetscher, Christian A., Louis, Patrick J., Lubek, Joshua E., Lugo, Ricardo, Lyford-Pike, Sofia, Kushner, George M., MacIver, Colin, MacLeod, Stephen P.R., Magraw, Caitlin B.L., Makhoul, Nicholas M., Manlove, Ashley E., Mardini, Samir, Markiewicz, Michael R., Marschall, Jeffrey S., Matthews, Nigel Shaun, McCain, Joseph P., McCoy, J. Michael, McKenna, Samuel J., Meara, Daniel J., Medeiros, Paulo Jose, Mehra, Pushkar, Mercuri, Louis G., Miles, Brett A., Miller, Meagan, Moe, Justine, Moon, Hwi Sean, Silva, Marina Morante, Morris, Christopher, Morton, Dean, Movahed, Reza, Mujica, Elena, Nadeau, Robert, Nathan, John M., Ness, Gregory M., Norbutt, Craig, Nuveen, Erik Jon, Obeid, George, Okay, Devin Joseph, Olivieri, Petra, Ord, Robert, Oreadi, Daniel, Panchal, Neeraj, Parmar, Sat, Patel, Ashish A., Peacock, Zachary S., Pennau, Karl, Perciaccante, Vincent J., Perenack, Jon D., Petukhova, Yuliya, Pfeiffer, Laurence D., Pham, Matthew H., Phelan, John N., Pi-Anfruns, Joan, Pierce, Brendan H.G., Pinkston, Daniel Joseph, Polido, Waldemar D., Posnick, Jeffrey C., Powers, David B., Prange-Kiel, Janine, Praveen, Prav, Precious, David S., Quereshy, Faisal A., Quinn, Peter D., Radant, Matthew, Ray, Christopher K., Read-Fuller, Andrew, Reddy, Likith, Renapurkar, Shravan, Reyneke, Johan P., Ritto, Fabio G., Robertson, Carrie E., Rogers, Jason, Ruggiero, Brian Louis, Ruiz, Ramon L., Sabino, Mary Ann C., Sabooree, Sepideh, Salama, Andrew, Salinas, Thomas J., Samman, Nabil, Sauerbier, Sebastian, Schlieve, Thomas, Schlissel, Edward R., Schmelzeisen, Rainer, Shand, Jocelyn M., Sharma, Kaushik H., Shirley, Brett, Shivers, Paul, Shupak, Raymond P., Van Sickels, Joseph E., Sinn, Douglas P., Smith, Kevin, Smith, Miller H., Soletic, Luke C., Stanek, Joel, Stanton, David, Steed, Martin B., Stevens, Mark, Suchyta, Marissa, Sullivan, Steven M., Sulyman, Omotara, Susarla, Srinivas M., Sylvester, David Knight, II, Talmant, Jean-Claude, Tandon, Rahul, Thakker, Jayini, Thayer, Stone, Tiwana, Paul S., Tolomeo, Pasquale G., Tran, Dan Q., Treasure, Trevor E., Trent, David C., Triplett, R. Gilbert, Tull, Greg, Turner, Michael D., Turvey, Timothy A., Uppgaard, Rachel, Vigliante, Craig E., Viozzi, Christopher F., Vorrasi, John, Waite, Peter D., Wan, Kenneth, Ward, Brent B., Wentland, Todd R., Williams, Fayette C., Woerner, Jennifer E., Wolford, Larry M., Wong, Patrick, Woo, Brian M., Wrzosek, Mariusz K., Yamashita, Duke, Yates, David M., Yeoh, Melvyn, Ying, Yedeh, Zakhary, George, and Zuniga, John R.
- Published
- 2024
- Full Text
- View/download PDF
213. Pre-existing psychological depression confers increased risk of adverse cardiovascular outcomes following cardiac surgery: A systematic review and meta-analysis
- Author
-
Flaherty, Lauren B., Wood, Taylor, Cheng, Allen, and Khan, Abdur R.
- Published
- 2017
- Full Text
- View/download PDF
214. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19:The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial
- Author
-
Angus, Derek C, Derde, Lennie, Al-Beidh, Farah, Annane, Djillali, Arabi, Yaseen, Beane, Abigail, van Bentum-Puijk, Wilma, Berry, Lindsay, Bhimani, Zahra, Bonten, Marc, Bradbury, Charlotte, Brunkhorst, Frank, Buxton, Meredith, Buzgau, Adrian, Cheng, Allen C, de Jong, Menno, Detry, Michelle, Estcourt, Lise, Fitzgerald, Mark, Goossens, Herman, Green, Cameron, Haniffa, Rashan, Higgins, Alisa M, Horvat, Christopher, Hullegie, Sebastiaan J, Kruger, Peter, Lamontagne, Francois, Lawler, Patrick R, Linstrum, Kelsey, Litton, Edward, Lorenzi, Elizabeth, Marshall, John, McAuley, Daniel, McGlothin, Anna, McGuinness, Shay, McVerry, Bryan, Montgomery, Stephanie, Mouncey, Paul, Murthy, Srinivas, Nichol, Alistair, Parke, Rachael, Parker, Jane, Rowan, Kathryn, Sanil, Ashish, Santos, Marlene, Saunders, Christina, Seymour, Christopher, Turner, Anne, van de Veerdonk, Frank, Venkatesh, Balasubramanian, Zarychanski, Ryan, Berry, Scott, Lewis, Roger J, McArthur, Colin, Webb, Steven A, Gordon, Anthony C, Writing Committee for the REMAP-CAP Investigators, Angus, Derek, Cheng, Allen, De Jong, Menno, Gordon, Anthony, Lawler, Patrick, Webb, Steve, Campbell, Lewis, Forbes, Andrew, Gattas, David, Heritier, Stephane, Higgins, Lisa, Peake, Sandra, Presneill, Jeffrey, Seppelt, Ian, Trapani, Tony, Young, Paul, Bagshaw, Sean, Daneman, Nick, Ferguson, Niall, Misak, Cheryl, Hullegie, Sebastiaan, Pletz, Mathias, Rohde, Gernot, Rowan, Kathy, Alexander, Brian, Basile, Kim, Girard, Timothy, Huang, David, Vates, Jennifer, Beasley, Richard, Fowler, Robert, McGloughlin, Steve, Morpeth, Susan, Paterson, David, Venkatesh, Bala, Uyeki, Tim, Baillie, Kenneth, Duffy, Eamon, Fowler, Rob, Hills, Thomas, Orr, Katrina, Patanwala, Asad, Tong, Steve, Netea, Mihai, Bihari, Shilesh, Carrier, Marc, Fergusson, Dean, Goligher, Ewan, Haidar, Ghady, Hunt, Beverley, Kumar, Anand, Laffan, Mike, Lawless, Patrick, Lother, Sylvain, McCallum, Peter, Middeldopr, Saskia, McQuilten, Zoe, Neal, Matthew, Pasi, John, Schutgens, Roger, Stanworth, Simon, Turgeon, Alexis, Weissman, Alexandra, Adhikari, Neill, Anstey, Matthew, Brant, Emily, de Man, Angelique, Lamonagne, Francois, Masse, Marie-Helene, Udy, Andrew, Arnold, Donald, Begin, Phillipe, Charlewood, Richard, Chasse, Michael, Coyne, Mark, Cooper, Jamie, Daly, James, Gosbell, Iain, Harvala-Simmonds, Heli, Hills, Tom, MacLennan, Sheila, Menon, David, McDyer, John, Pridee, Nicole, Roberts, David, Shankar-Hari, Manu, Thomas, Helen, Tinmouth, Alan, Triulzi, Darrell, Walsh, Tim, Wood, Erica, Calfee, Carolyn, O’Kane, Cecilia, Shyamsundar, Murali, Sinha, Pratik, Thompson, Taylor, Young, Ian, Bihari, Shailesh, Hodgson, Carol, Laffey, John, McAuley, Danny, Orford, Neil, Neto, Ary, Lewis, Roger, McGlothlin, Anna, Miller, Eliza, Singh, Vanessa, Zammit, Claire, van Bentum Puijk, Wilma, Bouwman, Wietske, Mangindaan, Yara, Parker, Lorraine, Peters, Svenja, Rietveld, Ilse, Raymakers, Kik, Ganpat, Radhika, Brillinger, Nicole, Markgraf, Rene, Ainscough, Kate, Brickell, Kathy, Anjum, Aisha, Lane, Janis-Best, Richards-Belle, Alvin, Saull, Michelle, Wiley, Daisy, Bion, Julian, Connor, Jason, Gates, Simon, Manax, Victoria, van der Poll, Tom, Reynolds, John, van Beurden, Marloes, Effelaar, Evelien, Schotsman, Joost, Boyd, Craig, Harland, Cain, Shearer, Audrey, Wren, Jess, Clermont, Giles, Garrard, William, Kalchthaler, Kyle, King, Andrew, Ricketts, Daniel, Malakoutis, Salim, Marroquin, Oscar, Music, Edvin, Quinn, Kevin, Cate, Heidi, Pearson, Karen, Collins, Joanne, Hanson, Jane, Williams, Penny, Jackson, Shane, Asghar, Adeeba, Dyas, Sarah, Sutu, Mihaela, Murphy, Sheenagh, Williamson, Dawn, Mguni, Nhlanhla, Potter, Alison, Porter, David, Goodwin, Jayne, Rook, Clare, Harrison, Susie, Williams, Hannah, Campbell, Hilary, Lomme, Kaatje, Williamson, James, Sheffield, Jonathan, van’t Hoff, Willian, McCracken, Phobe, Young, Meredith, Board, Jasmin, Mart, Emma, Knott, Cameron, Smith, Julie, Boschert, Catherine, Affleck, Julia, Ramanan, Mahesh, D’Souza, Ramsy, Pateman, Kelsey, Shakih, Arif, Cheung, Winston, Kol, Mark, Wong, Helen, Shah, Asim, Wagh, Atul, Simpson, Joanne, Duke, Graeme, Chan, Peter, Cartner, Brittney, Hunter, Stephanie, Laver, Russell, Shrestha, Tapaswi, Regli, Adrian, Pellicano, Annamaria, McCullough, James, Tallott, Mandy, Kumar, Nikhil, Panwar, Rakshit, Brinkerhoff, Gail, Koppen, Cassandra, Cazzola, Federica, Brain, Matthew, Mineall, Sarah, Fischer, Roy, Biradar, Vishwanath, Soar, Natalie, White, Hayden, Estensen, Kristen, Morrison, Lynette, Smith, Joanne, Cooper, Melanie, Health, Monash, Shehabi, Yahya, Al-Bassam, Wisam, Hulley, Amanda, Whitehead, Christina, Lowrey, Julie, Gresha, Rebecca, Walsham, James, Meyer, Jason, Harward, Meg, Venz, Ellen, Williams, Patricia, Kurenda, Catherine, Smith, Kirsy, Smith, Margaret, Garcia, Rebecca, Barge, Deborah, Byrne, Deborah, Byrne, Kathleen, Driscoll, Alana, Fortune, Louise, Janin, Pierre, Yarad, Elizabeth, Hammond, Naomi, Bass, Frances, Ashelford, Angela, Waterson, Sharon, Wedd, Steve, McNamara, Robert, Buhr, Heidi, Coles, Jennifer, Schweikert, Sacha, Wibrow, Bradley, Rauniyar, Rashmi, Myers, Erina, Fysh, Ed, Dawda, Ashlish, Mevavala, Bhaumik, Litton, Ed, Ferrier, Janet, Nair, Priya, Buscher, Hergen, Reynolds, Claire, Santamaria, John, Barbazza, Leanne, Homes, Jennifer, Smith, Roger, Murray, Lauren, Brailsford, Jane, Forbes, Loretta, Maguire, Teena, Mariappa, Vasanth, Smith, Judith, Simpson, Scott, Maiden, Matthew, Bone, Allsion, Horton, Michelle, Salerno, Tania, Sterba, Martin, Geng, Wenli, Depuydt, Pieter, De Waele, Jan, De Bus, Liesbet, Fierens, Jan, Bracke, Stephanie, Reeve, Brenda, Dechert, William, Chassé, Michaël, Carrier, François Martin, Boumahni, Dounia, Benettaib, Fatna, Ghamraoui, Ali, Bellemare, David, Cloutier, Ève, Francoeur, Charles, Lamontagne, François, D’Aragon, Frédérick, Carbonneau, Elaine, Leblond, Julie, Vazquez-Grande, Gloria, Marten, Nicole, Wilson, Maggie, Albert, Martin, Serri, Karim, Cavayas, Alexandros, Duplaix, Mathilde, Williams, Virginie, Rochwerg, Bram, Karachi, Tim, Oczkowski, Simon, Centofanti, John, Millen, Tina, Duan, Erick, Tsang, Jennifer, Patterson, Lisa, English, Shane, Watpool, Irene, Porteous, Rebecca, Miezitis, Sydney, McIntyre, Lauralyn, Brochard, Laurent, Burns, Karen, Sandhu, Gyan, Khalid, Imrana, Binnie, Alexandra, Powell, Elizabeth, McMillan, Alexandra, Luk, Tracy, Aref, Noah, Andric, Zdravko, Cviljevic, Sabina, Đimoti, Renata, Zapalac, Marija, Mirković, Gordan, Baršić, Bruno, Kutleša, Marko, Kotarski, Viktor, Vujaklija Brajković, Ana, Babel, Jakša, Sever, Helena, Dragija, Lidija, Kušan, Ira, Vaara, Suvi, Pettilä, Leena, Heinonen, Jonna, Kuitunen, Anne, Karlsson, Sari, Vahtera, Annukka, Kiiski, Heikki, Ristimäki, Sanna, Azaiz, Amine, Charron, Cyril, Godement, Mathieu, Geri, Guillaume, Vieillard-Baron, Antoine, Pourcine, Franck, Monchi, Mehran, Luis, David, Mercier, Romain, Sagnier, Anne, Verrier, Nathalie, Caplin, Cecile, Siami, Shidasp, Aparicio, Christelle, Vautier, Sarah, Jeblaoui, Asma, Fartoukh, Muriel, Courtin, Laura, Labbe, Vincent, Leparco, Cécile, Muller, Grégoire, Nay, Mai-Anh, Kamel, Toufik, Benzekri, Dalila, Jacquier, Sophie, Mercier, Emmanuelle, Chartier, Delphine, Salmon, Charlotte, Dequin, PierreFrançois, Schneider, Francis, Morel, Guillaume, L’Hotellier, Sylvie, Badie, Julio, Berdaguer, Fernando Daniel, Malfroy, Sylvain, Mezher, Chaouki, Bourgoin, Charlotte, Megarbane, Bruno, Voicu, Sebastian, Deye, Nicolas, Malissin, Isabelle, Sutterlin, Laetitia, Guitton, Christophe, Darreau, Cédric, Landais, Mickaël, Chudeau, Nicolas, Robert, Alain, Moine, Pierre, Heming, Nicholas, Maxime, Virginie, Bossard, Isabelle, Nicholier, Tiphaine Barbarin, Colin, Gwenhael, Zinzoni, Vanessa, Maquigneau, Natacham, Finn, André, Kreß, Gabriele, Hoff, Uwe, Friedrich Hinrichs, Carl, Nee, Jens, Hagel, Stefan, Ankert, Juliane, Kolanos, Steffi, Bloos, Frank, Petros, Sirak, Pasieka, Bastian, Kunz, Kevin, Appelt, Peter, Schütze, Bianka, Kluge, Stefan, Nierhaus, Axel, Jarczak, Dominik, Roedl, Kevin, Weismann, Dirk, Frey, Anna, Klinikum Neukölln, Vivantes, Reill, Lorenz, Distler, Michael, Maselli, Astrid, Bélteczki, János, Magyar, István, Fazekas, Ágnes, Kovács, Sándor, Szőke, Viktória, Szigligeti, Gábor, Leszkoven, János, Collins, Daniel, Breen, Patrick, Frohlich, Stephen, Whelan, Ruth, McNicholas, Bairbre, Scully, Michael, Casey, Siobhan, Kernan, Maeve, Doran, Peter, O’Dywer, Michael, Smyth, Michelle, Hayes, Leanne, Hoiting, Oscar, Peters, Marco, Rengers, Els, Evers, Mirjam, Prinssen, Anton, Bosch Ziekenhuis, Jeroen, Simons, Koen, Rozendaal, Wim, Polderman, F, de Jager, P, Moviat, M, Paling, A, Salet, A, Rademaker, Emma, Peters, Anna Linda, de Jonge, E, Wigbers, J, Guilder, E, Butler, M, Cowdrey, Keri-Anne, Newby, Lynette, Chen, Yan, Simmonds, Catherine, McConnochie, Rachael, Ritzema Carter, Jay, Henderson, Seton, Van Der Heyden, Kym, Mehrtens, Jan, Williams, Tony, Kazemi, Alex, Song, Rima, Lai, Vivian, Girijadevi, Dinu, Everitt, Robert, Russell, Robert, Hacking, Danielle, Buehner, Ulrike, Williams, Erin, Browne, Troy, Grimwade, Kate, Goodson, Jennifer, Keet, Owen, Callender, Owen, Martynoga, Robert, Trask, Kara, Butler, Amelia, Schischka, Livia, Young, Chelsea, Lesona, Eden, Olatunji, Shaanti, Robertson, Yvonne, José, Nuno, Amaro dos Santos Catorze, Teodoro, de Lima Pereira, Tiago Nuno Alfaro, Neves Pessoa, Lucilia Maria, Castro Ferreira, Ricardo Manuel, Pereira Sousa Bastos, Joana Margarida, Aysel Florescu, Simin, Stanciu, Delia, Zaharia, Miahela Florentina, Kosa, Alma Gabriela, Codreanu, Daniel, Marabi, Yaseen, Al Qasim, Eman, Moneer Hagazy, Mohamned, Al Swaidan, Lolowa, Arishi, Hatim, Muñoz-Bermúdez, Rosana, Marin-Corral, Judith, Salazar Degracia, Anna, Parrilla Gómez, Francisco, Mateo López, Maria Isabel, Rodriguez Fernandez, Jorge, Cárcel Fernández, Sheila, Carmona Flores, Rosario, León López, Rafael, de la Fuente Martos, Carmen, Allan, Angela, Polgarova, Petra, Farahi, Neda, McWilliam, Stephen, Hawcutt, Daniel, Rad, Laura, O’Malley, Laura, Whitbread, Jennifer, Kelsall, Olivia, Wild, Laura, Thrush, Jessica, Wood, Hannah, Austin, Karen, Donnelly, Adrian, Kelly, Martin, O’Kane, Sinéad, McClintock, Declan, Warnock, Majella, Johnston, Paul, Gallagher, Linda Jude, Mc Goldrick, Clare, Mc Master, Moyra, Strzelecka, Anna, Jha, Rajeev, Kalogirou, Michael, Ellis, Christine, Krishnamurthy, Vinodh, Deelchand, Vashish, Silversides, Jon, McGuigan, Peter, Ward, Kathryn, O’Neill, Aisling, Finn, Stephanie, Phillips, Barbara, Mullan, Dee, Oritz-Ruiz de Gordoa, Laura, Thomas, Matthew, Sweet, Katie, Grimmer, Lisa, Johnson, Rebekah, Pinnell, Jez, Robinson, Matt, Gledhill, Lisa, Wood, Tracy, Morgan, Matt, Cole, Jade, Hill, Helen, Davies, Michelle, Antcliffe, David, Templeton, Maie, Rojo, Roceld, Coghlan, Phoebe, Smee, Joanna, Mackay, Euan, Cort, Jon, Whileman, Amanda, Spencer, Thomas, Spittle, Nick, Kasipandian, Vidya, Patel, Amit, Allibone, Suzanne, Genetu, Roman Mary, Ramali, Mohamed, Ghosh, Alison, Bamford, Peter, London, Emily, Cawley, Kathryn, Faulkner, Maria, Jeffrey, Helen, Smith, Tim, Brewer, Chris, Gregory, Jane, Limb, James, Cowton, Amanda, O’Brien, Julie, Nikitas, Nikitas, Wells, Colin, Lankester, Liana, Pulletz, Mark, Birch, Jenny, Wiseman, Sophie, Horton, Sarah, Alegria, Ana, Turki, Salah, Elsefi, Tarek, Crisp, Nikki, Allen, Louise, McCullagh, Iain, Robinson, Philip, Hays, Carole, Babio-Galan, Maite, Stevenson, Hannah, Khare, Divya, Pinder, Meredith, Selvamoni, Selvin, Gopinath, Amitha, Pugh, Richard, Menzies, Daniel, Mackay, Callum, Allan, Elizabeth, Davies, Gwyneth, Puxty, Kathryn, McCue, Claire, Cathcart, Susanne, Hickey, Naomi, Ireland, Jane, Yusuff, Hakeem, Isgro, Graziella, Brightling, Chris, Bourne, Michelle, Craner, Michelle, Watters, Malcolm, Prout, Rachel, Davies, Louisa, Pegler, Suzannah, Kyeremeh, Lynsey, Arbane, Gill, Wilson, Karen, Gomm, Linda, Francia, Federica, Brett, Stephen, Sousa Arias, Sonia, Elin Hall, Rebecca, Budd, Joanna, Small, Charlotte, Birch, Janine, Collins, Emma, Henning, Jeremy, Bonner, Stephen, Hugill, Keith, Cirstea, Emanuel, Wilkinson, Dean, Karlikowski, Michal, Sutherland, Helen, Wilhelmsen, Elva, Woods, Jane, North, Julie, Sundaran, Dhinesh, Hollos, Laszlo, Coburn, Susan, Walsh, Joanne, Turns, Margaret, Hopkins, Phil, Smith, John, Noble, Harriet, Depante, Maria Theresa, Clarey, Emma, Laha, Shondipon, Verlander, Mark, Williams, Alexandra, Huckle, Abby, Hall, Andrew, Cooke, Jill, Gardiner-Hill, Caroline, Maloney, Carolyn, Qureshi, Hafiz, Flint, Neil, Nicholson, Sarah, Southin, Sara, Nicholson, Andrew, Borgatta, Barbara, Turner-Bone, Ian, Reddy, Amie, Wilding, Laura, Chamara Warnapura, Loku, Agno Sathianathan, Ronan, Golden, David, Hart, Ciaran, Jones, Jo, Bannard-Smith, Jonathan, Henry, Joanne, Birchall, Katie, Pomeroy, Fiona, Quayle, Rachael, Makowski, Arystarch, Misztal, Beata, Ahmed, Iram, KyereDiabour, Thyra, Naiker, Kevin, Stewart, Richard, Mwaura, Esther, Mew, Louise, Wren, Lynn, Willams, Felicity, Innes, Richard, Doble, Patricia, Hutter, Joanne, Shovelton, Charmaine, Plumb, Benjamin, Szakmany, Tamas, Hamlyn, Vincent, Hawkins, Nancy, Lewis, Sarah, Dell, Amanda, Gopal, Shameer, Ganguly, Saibal, Smallwood, Andrew, Harris, Nichola, Metherell, Stella, Lazaro, Juan Martin, Newman, Tabitha, Fletcher, Simon, Nortje, Jurgens, Fottrell-Gould, Deirdre, Randell, Georgina, Zaman, Mohsin, Elmahi, Einas, Jones, Andrea, Hall, Kathryn, Mills, Gary, Ryalls, Kim, Bowler, Helen, Sall, Jas, Bourne, Richard, Borrill, Zoe, Duncan, Tracey, Lamb, Thomas, Shaw, Joanne, Fox, Claire, Moreno Cuesta, Jeronimo, Xavier, Kugan, Purohit, Dharam, Elhassan, Munzir, Bakthavatsalam, Dhanalakshmi, Rowland, Matthew, Hutton, Paula, Bashyal, Archana, Davidson, Neil, Hird, Clare, Chhablani, Manish, Phalod, Gunjan, Kirkby, Amy, Archer, Simon, Netherton, Kimberley, Reschreiter, Henrik, Camsooksai, Julie, Patch, Sarah, Jenkins, Sarah, Pogson, David, Rose, Steve, Daly, Zoe, Brimfield, Lutece, Claridge, Helen, Parekh, Dhruv, Bergin, Colin, Bates, Michelle, Dasgin, Joanne, McGhee, Christopher, Sim, Malcolm, Hay, Sophie Kennedy, Henderson, Steven, Phull, Mandeep-Kaur, Zaidi, Abbas, Pogreban, Tatiana, Rosaroso, Lace Paulyn, Harvey, Daniel, Lowe, Benjamin, Meredith, Megan, Ryan, Lucy, Hormis, Anil, Walker, Rachel, Collier, Dawn, Kimpton, Sarah, Oakley, Susan, Rooney, Kevin, Rodden, Natalie, Hughes, Emma, Thomson, Nicola, McGlynn, Deborah, Walden, Andrew, Jacques, Nicola, Coles, Holly, Tilney, Emma, Vowell, Emma, Schuster-Bruce, Martin, Pitts, Sally, Miln, Rebecca, Purandare, Laura, Vamplew, Luke, Spivey, Michael, Bean, Sarah, Burt, Karen, Moore, Lorraine, Day, Christopher, Gibson, Charly, Gordon, Elizabeth, Zitter, Letizia, Keenan, Samantha, Baker, Evelyn, Cherian, Shiney, Cutler, Sean, Roynon-Reed, Anna, Harrington, Kate, Raithatha, Ajay, Bauchmuller, Kris, Ahmad, Norfaizan, Grecu, Irina, Trodd, Dawn, Martin, Jane, Wrey Brown, Caroline, Arias, Ana-Marie, Craven, Thomas, Hope, David, Singleton, Jo, Clark, Sarah, Rae, Nicola, Welters, Ingeborg, Hamilton, David Oliver, Williams, Karen, Waugh, Victoria, Shaw, David, Puthucheary, Zudin, Martin, Timothy, Santos, Filipa, Uddin, Ruzena, Somerville, Alastair, Tatham, Kate Colette, Jhanji, Shaman, Black, Ethel, Dela Rosa, Arnold, Howle, Ryan, Tully, Redmond, Drummond, Andrew, Dearden, Joy, Philbin, Jennifer, Munt, Sheila, Vuylsteke, Alain, Chan, Charles, Victor, Saji, Matsa, Ramprasad, Gellamucho, Minerva, Creagh-Brown, Ben, Tooley, Joe, Montague, Laura, De Beaux, Fiona, Bullman, Laetitia, Kersiake, Ian, Demetriou, Carrie, Mitchard, Sarah, Ramos, Lidia, White, Katie, Donnison, Phil, Johns, Maggie, Casey, Ruth, Mattocks, Lehentha, Salisbury, Sarah, Dark, Paul, Claxton, Andrew, McLachlan, Danielle, Slevin, Kathryn, Lee, Stephanie, Hulme, Jonathan, Joseph, Sibet, Kinney, Fiona, Senya, Ho Jan, Oborska, Aneta, Kayani, Abdul, Hadebe, Bernard, Orath Prabakaran, Rajalakshmi, Nichols, Lesley, Thomas, Matt, Worner, Ruth, Faulkner, Beverley, Gendall, Emma, Hayes, Kati, Hamilton-Davies, Colin, Chan, Carmen, Mfuko, Celina, Abbass, Hakam, Mandadapu, Vineela, Leaver, Susannah, Forton, Daniel, Patel, Kamal, Paramasivam, Elankumaran, Powell, Matthew, Gould, Richard, Wilby, Elizabeth, Howcroft, Clare, Banach, Dorota, Fernández de Pinedo Artaraz, Ziortza, Cabreros, Leilani, White, Ian, Croft, Maria, Holland, Nicky, Pereira, Rita, Zaki, Ahmed, Johnson, David, Jackson, Matthew, Garrard, Hywel, Juhaz, Vera, Roy, Alistair, Rostron, Anthony, Woods, Lindsey, Cornell, Sarah, Pillai, Suresh, Harford, Rachel, Rees, Tabitha, Ivatt, Helen, Sundara Raman, Ajay, Davey, Miriam, Lee, Kelvin, Barber, Russell, Chablani, Manish, Brohi, Farooq, Jagannathan, Vijay, Clark, Michele, Purvis, Sarah, Wetherill, Bill, Dushianthan, Ahilanandan, Cusack, Rebecca, de Courcy-Golder, Kim, Smith, Simon, Jackson, Susan, Attwood, Ben, Parsons, Penny, Page, Valerie, Zhao, Xiao Bei, Oza, Deepali, Rhodes, Jonathan, Anderson, Tom, Morris, Sheila, Xia Le Tai, Charlotte, Thomas, Amy, Keen, Alexandra, Digby, Stephen, Cowley, Nicholas, Southern, David, Reddy, Harsha, Campbell, Andy, Watkins, Claire, Smuts, Sara, Touma, Omar, Barnes, Nicky, Alexander, Peter, Felton, Tim, Ferguson, Susan, Sellers, Katharine, Bradley-Potts, Joanne, Yates, David, Birkinshaw, Isobel, Kell, Kay, Marshall, Nicola, Carr-Knott, Lisa, Writing Committee for the REMAP-CAP Investigators, Menon, David [0000-0002-3228-9692], Apollo - University of Cambridge Repository, Medical Microbiology and Infection Prevention, and AII - Infectious diseases
- Subjects
Male ,Hydrocortisone ,Anti-Inflammatory Agents ,lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4] ,01 natural sciences ,law.invention ,0302 clinical medicine ,Randomized controlled trial ,law ,Adrenal Cortex Hormones ,Clinical endpoint ,Medicine ,030212 general & internal medicine ,Hydrocortisone/administration & dosage ,Original Investigation ,2. Zero hunger ,Mortality rate ,Shock ,Covid19 ,General Medicine ,Middle Aged ,Intensive care unit ,3. Good health ,Intensive Care Units ,Treatment Outcome ,Early Termination of Clinical Trials ,Corticosteroid ,Female ,Coronavirus Infections ,medicine.drug ,Adult ,medicine.medical_specialty ,Respiration, Artificial/statistics & numerical data ,medicine.drug_class ,Anti-Inflammatory Agents/administration & dosage ,Pneumonia, Viral ,UNCOVER ,Adrenal Cortex Hormones/therapeutic use ,03 medical and health sciences ,Betacoronavirus ,All institutes and research themes of the Radboud University Medical Center ,Internal medicine ,Humans ,0101 mathematics ,Adverse effect ,Pandemics ,business.industry ,SARS-CoV-2 ,010102 general mathematics ,COVID-19 ,Odds ratio ,Coronavirus Infections/drug therapy ,Pneumonia, Viral/drug therapy ,Respiration, Artificial ,COVID-19 Drug Treatment ,Shock/drug therapy ,Human medicine ,business - Abstract
Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited.Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19.Design, Setting, and Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020.Interventions: The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (n = 143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (n = 152), or no hydrocortisone (n = 108).Main Outcomes and Measures: The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%).Results: After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (n = 137), shock-dependent (n = 146), and no (n = 101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0 (IQR, -1 to 15), 0 (IQR, -1 to 13), and 0 (-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively.Conclusions and Relevance: Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions.Trial Registration: ClinicalTrials.gov Identifier: NCT02735707.
- Published
- 2020
- Full Text
- View/download PDF
215. Ethical Problems Of Evaluating A New Treatment For Melioidosis
- Author
-
Cheng, Allen C., Lowe, Michael, Stephens, Dianne P., and Currie, Bart J.
- Published
- 2003
216. Influenza hospitalizations in Australian children 2010–2019: The impact of medical comorbidities on outcomes, vaccine coverage, and effectiveness
- Author
-
Norman, Daniel A., primary, Cheng, Allen C., additional, Macartney, Kristine K., additional, Moore, Hannah C., additional, Danchin, Margie, additional, Seale, Holly, additional, McRae, Jocelynne, additional, Clark, Julia E., additional, Marshall, Helen S., additional, Buttery, Jim, additional, Francis, Joshua R., additional, Crawford, Nigel W., additional, and Blyth, Christopher C., additional
- Published
- 2021
- Full Text
- View/download PDF
217. Are SABs equally preventable? development of a tool by Delphi method to help hospitals target the modifiable risk factors causing SAB infections
- Author
-
Karanfilovska, Daniela, primary, Cheng, Allen, additional, Spelman, Denis, additional, and Worth, Leon, additional
- Published
- 2021
- Full Text
- View/download PDF
218. Prospective characterisation of SARS-CoV-2 infections among children presenting to tertiary paediatric hospitals across Australia in 2020: a national cohort study
- Author
-
Wurzel, Danielle, primary, McMinn, Alissa, additional, Hoq, Monsurul, additional, Blyth, Christopher C, additional, Burgner, David, additional, Tosif, Shidan, additional, Buttery, Jim, additional, Carr, Jeremy, additional, Clark, Julia E, additional, Cheng, Allen C, additional, Dinsmore, Nicole, additional, Francis, Joshua Reginald, additional, Kynaston, Anne, additional, Lucas, Ryan, additional, Marshall, Helen, additional, McMullan, Brendan, additional, Singh-Grewal, Davinder, additional, Wood, Nicholas, additional, Macartney, Kristine, additional, Britton, Philip N, additional, and Crawford, Nigel W, additional
- Published
- 2021
- Full Text
- View/download PDF
219. Epidemiology of Kawasaki disease in Australia using two nationally complete datasets
- Author
-
Lucas, Ryan, primary, Dennington, Peta, additional, Wood, Erica, additional, Murray, Kevin J, additional, Cheng, Allen, additional, Burgner, David, additional, and Singh‐Grewal, Davinder, additional
- Published
- 2021
- Full Text
- View/download PDF
220. ATAGI 2021 annual statement on immunisation (Last updated: 19 September 2021)
- Author
-
Tran, Catherine, primary, Chiu, Clayton, additional, Cheng, Allen C, additional, Crawford, Nigel W, additional, Giles, Michelle L, additional, Macartney, Kristine K, additional, and Blyth, Christopher C, additional
- Published
- 2021
- Full Text
- View/download PDF
221. Integrated immune networks in SARS-CoV-2 infected pregnant women reveal differential NK cell and unconventional T cell activation
- Author
-
Kedzierska, Katherine, primary, Habel, Jennifer, additional, Chua, Brendon, additional, Kedzierski, Lukasz, additional, Selva, Kevin, additional, Damelang, Timon, additional, Haycroft, Ebene, additional, Nguyen, Thi, additional, Koay, Hui-Fern, additional, Nicholson, Suellen, additional, McQuilten, Hayley, additional, Jia, Xiaoxiao, additional, Allen, Lilith, additional, Hensen, Luca, additional, Zhang, Wuji, additional, de Sandt, Carolien van, additional, Neil, Jessica, additional, Amanat, Fatima, additional, Krammer, Florian, additional, Wragg, Kathleen, additional, Juno, Jennifer, additional, Wheatley, Adam, additional, Tan, Hyon-Xhi, additional, Pell, Gabrielle, additional, Audsley, Jennifer, additional, Thevarajan, Irani, additional, Denholm, Justin, additional, Subbarao, Kanta, additional, Godfrey, Dale, additional, Cheng, Allen, additional, Tong, Steven, additional, Bond, Katherine, additional, Williamson, Deborah, additional, James, Fiona, additional, Holmes, Natasha, additional, Smibert, Olivia, additional, Trubiona, Jason, additional, Gordon, Claire, additional, Chung, Amy, additional, Whitehead, Clare, additional, Kent, Stephen, additional, Lappas, Martha, additional, and Rowntree, Louise, additional
- Published
- 2021
- Full Text
- View/download PDF
222. Maternal Vaccination and Infant Influenza and Pertussis
- Author
-
Rowe, Stacey L., primary, Leder, Karin, additional, Perrett, Kirsten P., additional, Romero, Nicole, additional, Nolan, Terry M., additional, Stephens, Nicola, additional, Cowie, Benjamin C., additional, and Cheng, Allen C., additional
- Published
- 2021
- Full Text
- View/download PDF
223. The state of TRUS biopsy sepsis: readmissions to Victorian hospitals with TRUS biopsy-related infection over 5 years
- Author
-
Roth, Hedley, Millar, Jeremy L, Cheng, Allen C, Byrne, Amanda, Evans, Sue, and Grummet, Jeremy
- Published
- 2015
- Full Text
- View/download PDF
224. Use of non-pharmaceutical interventions to reduce the transmission of influenza in adults: A systematic review
- Author
-
SMITH, Sheree M.S., SONEGO, Sandra, WALLEN, Gwenyth R., WATERER, Grant, CHENG, Allen C., and THOMPSON, Philip
- Published
- 2015
- Full Text
- View/download PDF
225. ASSESSMENT OF TUMOR INFILTRATING LYMPHOCYTES FOLLOWING SURGICAL RESECTION MAY PREDICT RECURRENCE AND IDENTIFY THERAPEUTIC TARGETS IN HEAD AND NECK SQUAMOUS CELL CARCINOMA: OP047.
- Author
-
Bell, Bryan R., Feng, Zipei, Paustian, Christopher, Moudgil, Tarsem, Cheng, Allen, Dubay, Christopher, Bui, Tuan, Hulett, Tyler, Leidner, Rom, Urba, Walter J., Bifulco, Carlo B, and Fox, Bernard A
- Published
- 2015
226. Variation in health care-associated infection surveillance practices in Australia
- Author
-
Russo, Philip L., Cheng, Allen C., Richards, Michael, Graves, Nicholas, and Hall, Lisa
- Published
- 2015
- Full Text
- View/download PDF
227. Delayed Administration of Antibiotics and Mortality in Patients With Community-Acquired Pneumonia
- Author
-
Cheng, Allen C. and Buising, Kirsty L.
- Published
- 2009
- Full Text
- View/download PDF
228. Prostatic Abscess Due to Burkholderia pseudomallei: 81 Cases From a 19-Year Prospective Melioidosis Study
- Author
-
Morse, Levi P., Moller, Cea-Cea B., Harvey, Elizabeth, Ward, Linda, Cheng, Allen C., Carson, Phillip J., and Currie, Bart J.
- Published
- 2009
- Full Text
- View/download PDF
229. From neuromuscular activation to end-point locomotion: An artificial neural network-based technique for neural prostheses
- Author
-
Chang, Chia-Lin, Jin, Zhanpeng, Chang, Hou-Cheng, and Cheng, Allen C.
- Published
- 2009
- Full Text
- View/download PDF
230. Multicentre stepped-wedge cluster randomised controlled trial of an antimicrobial stewardship programme in residential aged care: protocol for the START trial
- Author
-
Jokanovic, Natali, Haines, Terry, Cheng, Allen C, Holt, Kathryn E, Hilmer, Sarah N, Jeon, Yun-Hee, Stewardson, Andrew J, Stuart, Rhonda L, Spelman, Tim, Peel, Trisha N, Peleg, Anton Y, and START Trial Group
- Abstract
INTRODUCTION: Antimicrobial resistance is a growing global health threat, driven by increasing inappropriate use of antimicrobials. High prevalence of unnecessary use of antimicrobials in residential aged care facilities (RACFs) has driven demand for the development and implementation of antimicrobial stewardship (AMS) programmes. The Stepped-wedge Trial to increase antibiotic Appropriateness in Residential aged care facilities and model Transmission of antimicrobial resistance (START) will implement and evaluate the impact of a nurse-led AMS programme on antimicrobial use in 12 RACFs. METHODS AND ANALYSIS: The START trial will implement and evaluate a nurse-led AMS programme via a stepped-wedge cluster randomised controlled trial design in 12 RACFs over 16 months. The AMS programme will incorporate education, aged care-specific treatment guidelines, documentation forms, and audit and feedback strategies that will target aged care staff, general practitioners, pharmacists, and residents and their families. The intervention will primarily focus on urinary tract infections, lower respiratory tract infections, and skin and soft tissue infections. RACFs will transition from control to intervention phases in random order, two at a time, every 2 months, with a 2-month transition, wash-in period. The primary outcome is the cumulative proportion of residents within each facility prescribed an antibiotic during each month and total days of antibiotic use per 1000 occupied bed days. Secondary outcomes include the number of courses of systemic antimicrobial therapy, antimicrobial appropriateness, antimicrobial resistant organisms, Clostridioides difficile infection, change in antimicrobial susceptibility profiles, hospitalisations and all-cause mortality. Analyses will be conducted according to the intention-to-treat principle. ETHICS AND DISSEMINATION: Ethics approval has been granted by the Alfred Hospital Human Research Ethics Committee (HREC/18/Alfred/591). Research findings will be disseminated through peer-reviewed publications, conferences and summarised reports provided to participating RACFs. TRIAL REGISTRATION NUMBER: NCT03941509.
- Published
- 2021
231. Treating mild COVID-19: What therapeutic options are available?
- Author
-
BARBER, BRIDGET E., TURNER, TARI, WHITE, HEATH, CHENG, ALLEN C., and MCGLOUGHLIN, STEVE A.
- Subjects
COVID-19 ,BRONCHIECTASIS ,BRUTON tyrosine kinase ,SARS-CoV-2 Omicron variant ,PLASMA cell diseases ,HEALTH facilities - Abstract
The article presents the discussion on rapid introduction of new treatments for mild COVID-19. Topics include treatment options for suitable patients with mild COVID-19 containing antivirals and monoclonal antibodies with the oral antivirals being most relevant for GPs; and symptomatic infection being lower for Omicron compared with Delta variants where effectiveness remaining high against hospitalisation and death.
- Published
- 2022
232. Travel-associated illness trends and clusters, 2000-2010
- Author
-
Leder, Karin, Torresi, Joseph, Brownstein, John S., Wilson, Mary E., Keystone, Jay S., Barnett, Elizabeth, Schwartz, Eli, Schlagenhauf, Patricia, Wilder-Smith, Annelies, Castelli, Francesco, von Sonnenburg, Frank, Freedman, David O., and Cheng, Allen C.
- Subjects
Communicable diseases -- Risk factors ,Travel industry -- Health aspects ,Travelers -- Health aspects ,Health - Abstract
International travel is markedly increasing. In 2010, an estimated 940 million tourists arrived at international destinations, more than twice the 435 million in 1990 (1). Trips to developing regions have [...]
- Published
- 2013
- Full Text
- View/download PDF
233. Chapter Editors and Contributors
- Author
-
Kademani, Deepak, primary, Steed, Martin B., additional, Khan, Husain Ali, additional, Meyer, Roger A., additional, Adams, Nathan G., additional, DMD, Neil Agnihotri, additional, Al-Bustani, Saif, additional, Allen, John M., additional, Anderson, Bruce W., additional, Assael, Leon A., additional, Attia, Robert S., additional, Aziz, Shahid R., additional, Bagheri, Shahrokh C., additional, Beckley, Michael L., additional, Bell, R. Bryan, additional, Bobek, Samuel, additional, Bouloux, Gary F., additional, Bradshaw, Shenan, additional, Bui, Tuan G., additional, Cheng, Allen, additional, Cho, Sung Hee, additional, Cunningham, Danielle M., additional, Dierks, Eric, additional, Doughan, Abdulrahman, additional, Farhidvash, Fariba, additional, Farish, Sam E., additional, Girn, Jaspal, additional, Haron, Ibrahim M., additional, Holmgren, Eric P., additional, Huffman, Bradford, additional, Jamali, Jason A., additional, Jimenez, Damian R., additional, Jo, Chris, additional, Jo, Jenny, additional, Johnson, Jeremiah O., additional, Kademani, Deepak, additional, Kao, Solon, additional, Kinard, Brian E., additional, Kolokythas, Antonia, additional, Krishnan, Deepak G., additional, Lee, Joyce T., additional, Louis, Patrick J., additional, Markiewicz, Michael R., additional, Marx, Robert E., additional, McKenzie, Wm. Stuart, additional, Mehrabi, Mehran, additional, Miloro, Michael, additional, Moe, Justine, additional, Mohammadzadeh, Kambiz, additional, Morlandt, Anthony B.P., additional, Osborn, Timothy M., additional, Paquin, Rebecca, additional, Park, Etern S., additional, Patel, Ketan, additional, Patel, Kumar J., additional, Patel, Mayoor, additional, Patel, Piyushkumar P., additional, Pathak, Sandeep V., additional, Perciaccante, Vincent J., additional, Rahimi, Ali R., additional, Rieck, Kevin L., additional, Sabino, Ma’Ann C., additional, Salgueiro, Martin, additional, Schlissel, Edward R., additional, Shahriari, Abtin, additional, Shum, Jonathan, additional, Sittitavornwong, Somsak, additional, Sodeifi, A. Michael, additional, Ueeck, Brett A., additional, Verschueren, David, additional, Whitesides, Lee M., additional, and Wilkinson, Michael, additional
- Published
- 2014
- Full Text
- View/download PDF
234. Biomarkers for the Early Diagnosis of Sepsis in Burns
- Author
-
Li, Andrew T., primary, Moussa, Anthony, additional, Gus, Eduardo, additional, Paul, Eldho, additional, Yii, Erwin, additional, Romero, Lorena, additional, Lin, Zhiliang Caleb, additional, Padiglione, Alexander, additional, Lo, Cheng Hean, additional, Cleland, Heather, additional, and Cheng, Allen C., additional
- Published
- 2021
- Full Text
- View/download PDF
235. Integrated immune networks in SARS-CoV-2 infected pregnant women reveal differential NK cell and unconventional T cell activation
- Author
-
Habel, Jennifer R, primary, Chua, Brendon Y, additional, Kedzierski, Lukasz, additional, Selva, Kevin J, additional, Damelang, Timon, additional, Haycroft, Ebene R, additional, Nguyen, Thi HO, additional, Koay, Hui-Fern, additional, Nicholson, Suellen, additional, McQuilten, Hayley, additional, Jia, Xiaoxiao, additional, Allen, Lilith F, additional, Hensen, Luca, additional, Zhang, Wuji, additional, van de Sandt, Carolien E, additional, Neil, Jessica A, additional, Amanat, Fatima, additional, Krammer, Florian, additional, Wragg, Kathleen, additional, Juno, Jennifer A, additional, Wheatley, Adam K, additional, Tan, Hyon-Xhi, additional, Pell, Gabrielle, additional, Audsley, Jennifer, additional, Thevarajan, Irani, additional, Denholm, Justin, additional, Subbarao, Kanta, additional, Godfrey, Dale I, additional, Cheng, Allen C, additional, Tong, Steven YC, additional, Bond, Katherine, additional, Williamson, Deborah A, additional, James, Fiona, additional, Holmes, Natasha E, additional, Smibert, Olivia C, additional, Trubiano, Jason A, additional, Gordon, Claire L, additional, Chung, Amy W, additional, Whitehead, Clare L, additional, Kent, Stephen J, additional, Lappas, Martha, additional, Rowntree, Louise C, additional, and Kedzierska, Katherine, additional
- Published
- 2021
- Full Text
- View/download PDF
236. The frequency of urinary tract infections and the value of antiseptics in community-dwelling people who undertake intermittent urinary catheterization: A systematic review
- Author
-
Mitchell, Brett G., primary, Prael, Grace, additional, Curryer, Cassie, additional, Russo, Philip L., additional, Fasugba, Oyebola, additional, Lowthian, Judy, additional, Cheng, Allen C., additional, Archibold, Jemma, additional, Robertson, Mark, additional, and Kiernan, Martin, additional
- Published
- 2021
- Full Text
- View/download PDF
237. Altered microRNA expression in COVID-19 patients enables identification of SARS-CoV-2 infection
- Author
-
Farr, Ryan J., primary, Rootes, Christina L., additional, Rowntree, Louise C., additional, Nguyen, Thi H. O., additional, Hensen, Luca, additional, Kedzierski, Lukasz, additional, Cheng, Allen C., additional, Kedzierska, Katherine, additional, Au, Gough G., additional, Marsh, Glenn A., additional, Vasan, Seshadri S., additional, Foo, Chwan Hong, additional, Cowled, Christopher, additional, and Stewart, Cameron R., additional
- Published
- 2021
- Full Text
- View/download PDF
238. AAA stewardship: managing high‐risk medications with dedicated antimicrobial, anticoagulation and analgesic stewardship programs
- Author
-
Bui, Thuy, primary, Bortz, Hadley, additional, Cairns, Kelly A., additional, Graudins, Linda V., additional, Corallo, Carmela E., additional, Konstantatos, Alex, additional, Tran, Huyen, additional, Cheng, Allen, additional, and Dooley, Michael J., additional
- Published
- 2021
- Full Text
- View/download PDF
239. Early antimicrobial stewardship team intervention on appropriateness of antimicrobial therapy in suspected sepsis: a randomized controlled trial
- Author
-
Rashidzada, Zohal, primary, Cairns, Kelly A, additional, Peel, Trisha N, additional, Jenney, Adam W, additional, Doyle, Joseph S, additional, Dooley, Michael J, additional, and Cheng, Allen C, additional
- Published
- 2021
- Full Text
- View/download PDF
240. A controlled human infection model of Streptococcus pyogenes pharyngitis (CHIVAS-M75): an observational, dose-finding study
- Author
-
Osowicki, Joshua, primary, Azzopardi, Kristy I, additional, Fabri, Loraine, additional, Frost, Hannah R, additional, Rivera-Hernandez, Tania, additional, Neeland, Melanie R, additional, Whitcombe, Alana L, additional, Grobler, Anneke, additional, Gutman, Sarah J, additional, Baker, Ciara, additional, Wong, Janet M F, additional, Lickliter, Jason D, additional, Waddington, Claire S, additional, Pandey, Manisha, additional, Schuster, Tibor, additional, Cheng, Allen C, additional, Pollard, Andrew J, additional, McCarthy, James S, additional, Good, Michael F, additional, Dale, James B, additional, Batzloff, Michael, additional, Moreland, Nicole J, additional, Walker, Mark J, additional, Carapetis, Jonathan R, additional, Smeesters, Pierre R, additional, and Steer, Andrew C, additional
- Published
- 2021
- Full Text
- View/download PDF
241. The best today for a better tomorrow: a standard of practice to both recognise and develop infectious diseases pharmacy
- Author
-
Cheng, Allen C., primary
- Published
- 2021
- Full Text
- View/download PDF
242. Absence of human papillomavirus in nasopharyngeal swabs from infants in a population at high risk of human papillomavirus infection
- Author
-
Smith‐Vaughan, Heidi C, primary, Cheng, Allen C, additional, Tabrizi, Sepehr N., additional, Wurzel, Danielle F, additional, Beissbarth, Jemima, additional, Leach, Amanda J, additional, Morris, Peter S, additional, Binks, Michael J, additional, Torzillo, Paul J, additional, Chang, Anne B, additional, and Marsh, Robyn L, additional
- Published
- 2021
- Full Text
- View/download PDF
243. Additional file 1 of Is antibiotic treatment effective in the management of chronic low back pain with disc herniation? Study protocol for a randomised controlled trial
- Author
-
Urquhart, Donna M., Rosenfeld, Jeffrey V., van Tulder, Maurits, Wluka, Anita E., Leder, Karin, Cheng, Allen C., Forbes, Andrew B., Chan, Patrick, O���Sullivan, Richard, Liew, Susan, and Cicuttini, Flavia M.
- Abstract
Additional file 1. SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents
- Published
- 2021
- Full Text
- View/download PDF
244. Absence of human papillomavirus in nasopharyngeal swabs from infants in a population at high risk of human papillomavirus infection
- Author
-
Smith-Vaughan, Heidi C., Cheng, Allen C., Tabrizi, Sepehr N., Wurzel, Danielle F., Beissbarth, Jemima, Leach, Amanda J., Morris, Peter S., Binks, Michael J., Torzillo, Paul J., Chang, Anne B., Marsh, Robyn L., Smith-Vaughan, Heidi C., Cheng, Allen C., Tabrizi, Sepehr N., Wurzel, Danielle F., Beissbarth, Jemima, Leach, Amanda J., Morris, Peter S., Binks, Michael J., Torzillo, Paul J., Chang, Anne B., and Marsh, Robyn L.
- Abstract
Maternal urogenital human papillomavirus (HPV) infection may place neonates at risk of HPV acquisition and subsequently lower respiratory infections as HPV can influence development of immunity. The respiratory HPV prevalence is not known in remote-dwelling Aboriginal infants, who are at high risk of respiratory infection and where the population prevalence of urogenital HPV in women is high. These data are necessary to inform HPV vaccination regimens. A retrospective analysis using PCR specific for HPV was performed on 64 stored nasopharyngeal swabs from remote-dwelling Aboriginal infants < 6 months of age, with and without hospitalised pneumonia. HPV DNA was not detected in any specimen. Despite the negative result, we cannot exclude a role for HPV in respiratory infections affecting infants in this population; however, our data do not support HPV as an important contributor to acute respiratory infection in remote-dwelling Aboriginal children.
- Published
- 2021
245. Dexamethasone and Surgical-Site Infection
- Author
-
ANZCA Clinical Trials Network, Chan, MTV, Corcoran, T, Ho, KM, Leslie, K, Myles, PS, O'Loughlin, E, Short, TG, Story, DA, PADDI Investigators, Australasian Society for Infectious Diseases Clinical Research Network, Corcoran Tomas B, Myles Paul S, Forbes Andrew B, Cheng Allen C, Bach Leon A, O'Loughlin Edmond, Leslie Kate, Chan Matthew TV, Story David, Short Timothy G, Martin Catherine, Coutts Pauline, Ho Kowk M, Australian and New Zealand College of Anaesthetists Clinical Trials Network, ANZCA Clinical Trials Network, Chan, MTV, Corcoran, T, Ho, KM, Leslie, K, Myles, PS, O'Loughlin, E, Short, TG, Story, DA, PADDI Investigators, Australasian Society for Infectious Diseases Clinical Research Network, Corcoran Tomas B, Myles Paul S, Forbes Andrew B, Cheng Allen C, Bach Leon A, O'Loughlin Edmond, Leslie Kate, Chan Matthew TV, Story David, Short Timothy G, Martin Catherine, Coutts Pauline, Ho Kowk M, and Australian and New Zealand College of Anaesthetists Clinical Trials Network
- Abstract
Background: The glucocorticoid dexamethasone prevents nausea and vomiting after surgery, but there is concern that it may increase the risk of surgical-site infection. less... Methods: In this pragmatic, international, noninferiority trial, we randomly assigned 8880 adult patients who were undergoing nonurgent, noncardiac surgery of at least 2 hours' duration, with a skin incision length longer than 5 cm and a postoperative overnight hospital stay, to receive 8 mg of intravenous dexamethasone or matching placebo while under anesthesia. Randomization was stratified according to diabetes status and trial center. The primary outcome was surgical-site infection within 30 days after surgery. The prespecified noninferiority margin was 2.0 percentage points. Results: A total of 8725 participants were included in the modified intention-to-treat population (4372 in the dexamethasone group and 4353 in the placebo group), of whom 13.2% (576 in the dexamethasone group and 572 in the placebo group) had diabetes mellitus. Of the 8678 patients included in the primary analysis, surgical-site infection occurred in 8.1% (354 of 4350 patients) assigned to dexamethasone and in 9.1% (394 of 4328) assigned to placebo (risk difference adjusted for diabetes status, -0.9 percentage points; 95.6% confidence interval [CI], -2.1 to 0.3; P<0.001 for noninferiority). The results for superficial, deep, and organ-space surgical-site infections and in patients with diabetes were similar to those of the primary analysis. Postoperative nausea and vomiting in the first 24 hours after surgery occurred in 42.2% of patients in the dexamethasone group and in 53.9% in the placebo group (risk ratio, 0.78; 95% CI, 0.75 to 0.82). Hyperglycemic events in patients without diabetes occurred in 22 of 3787 (0.6%) in the dexamethasone group and in 6 of 3776 (0.2%) in the placebo group. Conclusions: Dexamethasone was noninferior to placebo with respect to the incidence of surgical-site infection within 30 days after
- Published
- 2021
246. Prevalence of asymptomatic SARS-CoV-2 infection in elective surgical patients in Australia: a prospective surveillance study
- Author
-
Coatsworth, Nicholas, Myles, P. S., Mann, Graham, Cockburn, Ian, Forbes, A B, Gardiner, Elizabeth, Lum, Gary, Cheng, Allen, Gruen, Russell, Coatsworth, Nicholas, Myles, P. S., Mann, Graham, Cockburn, Ian, Forbes, A B, Gardiner, Elizabeth, Lum, Gary, Cheng, Allen, and Gruen, Russell
- Abstract
Background: The study aimed to estimate the prevalence of active or previous SARSCoV-2 infection in asymptomatic adults admitted for elective surgery in Australian hospitals. This surveillance activity was established as part of the National Pandemic Health Intelligence Plan. Methods: Participants (n = 3037) were recruited from 11 public and private hospitals in four states (NSW, Vic, SA and WA) between 2 June and 17 July 2020, with an overall 66% participation rate. Presence of SARS-CoV-2 viral RNA was assessed by Reverse Transcriptase - Polymerase Chain Reaction (RT-PCR) analysis of nasopharyngeal swabs taken after induction of anaesthesia. Presence of anti-SARS-CoV-2 antibodies was assessed by analysis of serum collected at the same time using a novel dual-antigen ELISA assay. Results: No patient (0/3010) returned a positive RT-PCR result. The Bayesian estimated prevalence of active infection of 0.02% (95% probability interval 0.00–0.11%), with the upper endpoint being 1 in 918. Positive serology (IgG) was observed in 15 of 2991 patients, with a strong positive in five of those individuals (Bayesian estimated seroprevalence 0.16%; 95% probability interval 0.00–0.47%). Conclusion: These results confirm that during periods of low community prevalence of SARS-CoV-2 elective surgery patients without fever or respiratory symptoms had a very low prevalence of active SARS-CoV-2 infection.
- Published
- 2021
247. A controlled human infection model of Streptococcus pyogenes pharyngitis (CHIVAS-M75): an observational, dose-finding study
- Author
-
Osowicki, Joshua, Azzopardi, Kristy, Fabri, Loraine, Frost, Hannah R C H., Rivera-Hernandez, Tania, Neeland, Melanie M.R., Whitcombe, Alana A.L., Grobler, Anneke, Gutman, Sarah S.J., Baker, Ciara A, Wong, Janet J.M.F., Lickliter, Jason J.D., Waddington, Claire Shelley, Pandey, Manisha, Schuster, Tibor, Cheng, Allen C, Pollard, Andrew A.J., McCarthy, James J.S., Good, Michael M.F., Dale, James B, Batzloff, Michael, Moreland, N.J., Walker, Mark J, Carapetis, Jonathan Rhys, Smeesters, Pierre, Steer, Andrew C, Osowicki, Joshua, Azzopardi, Kristy, Fabri, Loraine, Frost, Hannah R C H., Rivera-Hernandez, Tania, Neeland, Melanie M.R., Whitcombe, Alana A.L., Grobler, Anneke, Gutman, Sarah S.J., Baker, Ciara A, Wong, Janet J.M.F., Lickliter, Jason J.D., Waddington, Claire Shelley, Pandey, Manisha, Schuster, Tibor, Cheng, Allen C, Pollard, Andrew A.J., McCarthy, James J.S., Good, Michael M.F., Dale, James B, Batzloff, Michael, Moreland, N.J., Walker, Mark J, Carapetis, Jonathan Rhys, Smeesters, Pierre, and Steer, Andrew C
- Abstract
Background: Streptococcus pyogenes is a leading cause of infection-related morbidity and mortality. A reinvigorated vaccine development effort calls for new clinically relevant human S pyogenes experimental infection models to support proof of concept evaluation of candidate vaccines. We describe the initial Controlled Human Infection for Vaccination Against S pyogenes (CHIVAS-M75) study, in which we aimed to identify a dose of emm75 S pyogenes that causes acute pharyngitis in at least 60% of volunteers when applied to the pharynx by swab. Methods: This observational, dose-finding study was done in a clinical trials facility in Melbourne (VIC, Australia). Groups of healthy volunteers aged 18–40 years, at low risk of complicated S pyogenes disease, and without high type-specific anti-emm75 IgG antibodies against the challenge strain were challenged and closely monitored as inpatients for up to 6 days, and then as outpatients for 6 months. Antibiotics were started upon diagnosis (clinical signs and symptoms of pharyngitis and a positive rapid molecular test) or after 5 days in those without pharyngitis. Rapid test results were confirmed by standard bacterial culture. After a sentinel participant, cohorts of five and then ten participants were challenged, with protocol-directed dose-escalation or de-escalation for subsequent cohorts. The primary outcome was the proportion of participants at each dose level with pharyngitis by day 5 after challenge. The study is registered with ClinicalTrials.gov, NCT03361163. Findings: Between July 10, 2018, and Sept 23, 2019, 25 healthy adults were challenged with emm75 S pyogenes and included in analyses. Pharyngitis was diagnosed in 17 (85%; 95% CI 62–97) of 20 participants at the starting dose level (1–3 × 105 colony-forming units [CFU]/mL). This high proportion prompted dose de-escalation. At the lower dose level (1–3 × 104 CFU/mL), pharyngitis was diagnosed in one of five participants. Immunological, biochemical, and microbiologi, SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2021
248. Control of fluoroquinolone resistance through successful regulation, Australia
- Author
-
Cheng, Allen C., Turnidge, John, Collignon, Peter, Looke, David, Barton, Mary, and Gottlieb, Thomas
- Subjects
Drug resistance in microorganisms -- Health aspects ,Antibacterial agents -- Health aspects ,Pharmaceutical policy -- Health aspects ,Health - Abstract
Nalidixic acid, the first quinolone introduced into clinical practice, was developed in the 1960s; its use was largely confined to the treatment of urinary tract infections. After the development of [...]
- Published
- 2012
- Full Text
- View/download PDF
249. Pandemic (H1N1) 2009 risk for frontline health care workers
- Author
-
Marshall, Caroline, Kelso, Anne, McBryde, Emma, Barr, Ian G., Eisen, Damon P., Sasadeusz, Joe, Buising, Kirsty, Cheng, Allen C., Johnson, Paul, and Richards, Michael
- Subjects
Commonwealth Serum Laboratories ,Workers -- Health aspects ,Viral antibodies -- Health aspects ,Cross infection -- Risk factors -- Health aspects ,Health care industry -- Health aspects ,Influenza -- Risk factors -- Health aspects ,Nosocomial infections -- Risk factors -- Health aspects ,Disease transmission -- Risk factors -- Health aspects ,Antibodies -- Health aspects ,Health care industry ,Health - Abstract
Australia was affected early in the (H1N1) 2009 influenza pandemic with 37,636 cases and 191 deaths reported. The state of Victoria was the first to observe a substantial peak in [...]
- Published
- 2011
- Full Text
- View/download PDF
250. Management of the N0 Neck in Oral Squamous Cell Carcinoma
- Author
-
Cheng, Allen and Schmidt, Brian L.
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.